Programme (all times are CET)
Wednesday 21 February
08.00 - 08.30   Registration, networking, refreshments
08.30 - 09.00   Welcome address
Caroline Rynn (Roche UK) and Heide Duevel (Merck KGaA Darmstadt)
    ADME session 1: Covering multiparameter ADME optimisation of TPDs and practical in vitro & in vivo challenges encountered
09.00 - 09.30   1-1 Physicochemical attributes and ADME optimization challenges of oral bifunctional degrader molecules
Andy Pike (AstraZeneca, UK)
09.30 - 10.00   1-2 When one size doesn’t fit all, DMPK screening optimisation of TPDs
Ed Hooper-Greenhill (GSK, UK)
10.00 - 10.30   1-3 PBPK modelling strategy of Protacs
Farzaneh Salem (GSK, UK)
10.30 - 11.00   Break/networking
    PKPD session: Covering PKPD properties of TPDs and application of integrated modeling frameworks to quantitatively predict full in vivo degradation profiles
11.00 - 11.30   2-1 Quantitative PKPD modelling for PROTACs
James Yates (GSK, UK)
11.30 - 12.00   2-2 PROTACs modelling: new challenges from compound optimization to translational PKPD
Sofia Guzzetti (AstraZeneca, UK)
12.00 - 12.30   2-3 PK/PD model-based predictions of targeted protein degraders: Translating in vitro degradation data to in vivo degradation profiles
Andreas Reichel (Bayer, DE)
12.30 - 13.30   Buffet lunch/networking
    Spotlight talks: Covering application of novel mathematical models to predict PKPD, model based assessment ofto identify the key drivers of efficacy, a mechanistic PK/PD modeling framework case example, IVIVE of TPD clearance, and prediction of IMHB-mediated PROTAC chameleonicity
13.30 - 13.45   3-1 Putting predictive PK/PD modeling of targeted protein degraders (TPDs) into practice: A case study from an oncology project
Robin Haid (Bayer, DE)
13.45 - 14.00   3-2 Current aspects on in vitro-in vivo extrapolation of PROTAC clearance
Christine K. Maurer (Merck KGaA Darmstadt, DE) 
14.00 - 14.15   3-3 Prediction of IMHB-mediated PROTAC chameleonicity
Diego Garcia Jimenez (University of Turin, IT)
14.15 - 14.30   3-4 Model-based assessment of pharmacological and pharmacokinetic properties of a molecular glue degrader for optimal target engagement
Uddipan Sarma (UCB, UK)
    ADME session 2: Covering in vitro and in vivo challenges of TPDs and novel delivery approaches to target the site of action
14.30 - 15.00   4-1 Preclinical Absorption of Protacs
Stefan Steyn (Pfizer, US) 
15.00 - 15.30   4-2 Delivery of PROTACs to the site of action
Donglu Zhang (Genentech, US)
15.30 - 16.00   Break/networking
16.00 - 16.30   ADME/PKPD round table Q&A
All presenters
16.30 - 17.00   Meeting highlights and future perspectives
Caroline Rynn (Roche UK) and Heide Duevel (Merck KGaA Darmstadt)
17.00   Meeting closes